Chemotherapy-Induced Nausea and Vomiting Drugs Market Size, Share, and Industry Analysis, By Drug Type (5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoid Receptor Agonist, and Others), By Application (Prophylaxis and Treatment), By Emetogenicity (Highly emetogenic chemotherapy (HEC), Moderately emetogenic chemotherapy (MEC), and Low/minimal emetogenic chemotherapy), By Route of Administration (Parenteral, Oral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Others), and Regional Forecast 2026-2034

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction
   1. Market Scope
   2. Market Segmentation
   3. Market Methodology
   4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities 
   4. Market Trends
4. Key Insights
   1. Prevalence of Cancer, By Key Regions, 2025
   2. Pipeline Analysis, By Key Players 
   3. Key Industry Developments (Strategic Partnerships, Collaborations, Acquisitions, and Mergers)
   4. Reimbursement Scenario by Key Countries/Regions
   5. New Product Launches, By Key Players
5. Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis, Insights and Forecast, 2021-2034 
   1. Market Analysis, Insights and Forecast – By Drug Type
      1. 5-HT3 Receptor Antagonists
      2. Neurokinin-1 Receptor Antagonists
      3. Corticosteroids
      4. Cannabinoid Receptor Agonist
      5. Others
   2. Market Analysis, Insights and Forecast – By Application
      1. Prophylaxis 
      2. Treatment
   3. Market Analysis, Insights and Forecast – By Emetogenicity
      1. Highly emetogenic chemotherapy (HEC)
      2. Moderately emetogenic chemotherapy (MEC)
      3. Low/minimal emetogenic chemotherapy 
   4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Parenteral
      2. Oral
      3. Others
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Others
   6. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
6. North America Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis, Insights and Forecast, 2021-2034
   1. Market Analysis, Insights and Forecast – By Drug Type
      1. 5-HT3 Receptor Antagonists
      2. Neurokinin-1 Receptor Antagonists
      3. Corticosteroids
      4. Cannabinoid Receptor Agonist
      5. Others
   2. Market Analysis, Insights and Forecast – By Application
      1. Prophylaxis 
      2. Treatment
   3. Market Analysis, Insights and Forecast – By Emetogenicity
      1. Highly emetogenic chemotherapy (HEC)
      2. Moderately emetogenic chemotherapy (MEC)
      3. Low/minimal emetogenic chemotherapy 
   4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Parenteral
      2. Oral
      3. Others
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Others
   6. Market Analysis, Insights and Forecast – By Country
      1. U.S. 
      2. Canada 
7.  Europe Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis, Insights and Forecast, 2021-2034
   1. Market Analysis, Insights and Forecast – By Drug Type
      1. 5-HT3 Receptor Antagonists
      2. Neurokinin-1 Receptor Antagonists
      3. Corticosteroids
      4. Cannabinoid Receptor Agonist
      5. Others
   2. Market Analysis, Insights and Forecast – By Application
      1. Prophylaxis 
      2. Treatment
   3. Market Analysis, Insights and Forecast – By Emetogenicity
      1. Highly emetogenic chemotherapy (HEC)
      2. Moderately emetogenic chemotherapy (MEC)
      3. Low/minimal emetogenic chemotherapy 
   4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Parenteral
      2. Oral
      3. Others
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Others
   6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. UK
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe 
8. Asia Pacific Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis, Insights and Forecast, 2021-2034
   1. Market Analysis, Insights and Forecast – By Drug Type
      1. 5-HT3 Receptor Antagonists
      2. Neurokinin-1 Receptor Antagonists
      3. Corticosteroids
      4. Cannabinoid Receptor Agonist
      5. Others
   2. Market Analysis, Insights and Forecast – By Application
      1. Prophylaxis 
      2. Treatment
   3. Market Analysis, Insights and Forecast – By Emetogenicity
      1. Highly emetogenic chemotherapy (HEC)
      2. Moderately emetogenic chemotherapy (MEC)
      3. Low/minimal emetogenic chemotherapy 
   4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Parenteral
      2. Oral
      3. Others
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Others
   6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific 
9. Latin America Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis, Insights and Forecast, 2021-2034
   1. Market Analysis, Insights and Forecast – By Drug Type
      1. 5-HT3 Receptor Antagonists
      2. Neurokinin-1 Receptor Antagonists
      3. Corticosteroids
      4. Cannabinoid Receptor Agonist
      5. Others
   2. Market Analysis, Insights and Forecast – By Application
      1. Prophylaxis 
      2. Treatment
   3. Market Analysis, Insights and Forecast – By Emetogenicity
      1. Highly emetogenic chemotherapy (HEC)
      2. Moderately emetogenic chemotherapy (MEC)
      3. Low/minimal emetogenic chemotherapy 
   4. Market Analysis, Insights and Forecast – By Route of Administration
      1. Parenteral
      2. Oral
      3. Others
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Others
   6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil 
      2. Mexico 
      3. Rest of Latin America
10. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Type
       1. 5-HT3 Receptor Antagonists
       2. Neurokinin-1 Receptor Antagonists
       3. Corticosteroids
       4. Cannabinoid Receptor Agonist
       5. Others
    2. Market Analysis, Insights and Forecast – By Application
       1. Prophylaxis 
       2. Treatment
    3. Market Analysis, Insights and Forecast – By Emetogenicity
       1. Highly emetogenic chemotherapy (HEC)
       2. Moderately emetogenic chemotherapy (MEC)
       3. Low/minimal emetogenic chemotherapy 
    4. Market Analysis, Insights and Forecast – By Route of Administration
       1. Parenteral
       2. Oral
       3. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel
       1. Hospital Pharmacies
       2. Retail Pharmacies & Drug Stores
       3. Others
    6. Market Analysis, Insights and Forecast – By Country/Sub-region
       1. South Africa
       2. GCC 
       3. Rest of Middle East & Africa
11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
       1. Merck & Co., Inc.
       2. Heron Therapeutics, Inc.
       3. Helsinn Healthcare SA
       4. Cumberland Pharmaceuticals Inc.
       5. Genentech, Inc.
       6. Novartis AG
       7. Bausch Health Companies Inc.
       8. Benuvia Manufacturing, LLC